Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy: preclinical basis
- PMID: 12902859
- DOI: 10.1097/01.COC.0000074160.49879.51
Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy: preclinical basis
Abstract
Cyclooxygenase-2 (COX-2), an enzyme induced by proinflammatory cytokines, mitogenic substances, oncogenes, growth factors, and hypoxia, among others, is involved in the metabolic conversion of arachidonic acid to prostaglandins in inflamed tissues and neoplasia. COX-2 is often overexpressed in malignant tumors and premalignant lesions and is linked to carcinogenesis, maintenance of progressive tumor growth, and facilitation of metastatic spread. Because COX-2 may also be a determinant of tumor radioresistance, its inhibition or inhibition of its products (prostaglandins) may improve tumor response to radiotherapy. Preclinical studies have shown that treatment with selective COX-2 inhibitors significantly enhances tumor response to radiation without appreciably affecting normal tissue radioresponse. The underlying mechanisms of the COX-2 inhibitor-radiation interactions seem to be multiple, with the enzyme inhibitor directly or indirectly augmenting tumor cell destruction by radiation. Thus, use of selective COX-2 inhibitors is a potential approach for improving cancer radiotherapy.
Similar articles
-
COX-2 inhibitor as a radiation enhancer: new strategies for the treatment of lung cancer.Am J Clin Oncol. 2003 Aug;26(4):S70-4. doi: 10.1097/01.COC.0000074161.92815.93. Am J Clin Oncol. 2003. PMID: 12902860 Review.
-
Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer.Am J Clin Oncol. 2003 Aug;26(4):S85-91. doi: 10.1097/01.COC.0000074307.55019.29. Am J Clin Oncol. 2003. PMID: 12902863 Review.
-
Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor.Cancer Res. 2000 Mar 1;60(5):1326-31. Cancer Res. 2000. PMID: 10728694
-
COX-2 inhibitors as radiosensitizing agents for cancer therapy.Am J Clin Oncol. 2003 Aug;26(4):S58-61. doi: 10.1097/01.COC.0000074158.59269.9F. Am J Clin Oncol. 2003. PMID: 12902857 Review.
-
Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse.Semin Radiat Oncol. 2001 Oct;11(4):290-9. doi: 10.1053/srao.2001.26018. Semin Radiat Oncol. 2001. PMID: 11677654 Review.
Cited by
-
Aza-BODIPY probe for selective visualization of cyclooxygenase-2 in cancer cells.RSC Adv. 2019 Apr 30;9(24):13372-13377. doi: 10.1039/c9ra01948k. eCollection 2019 Apr 30. RSC Adv. 2019. PMID: 35519572 Free PMC article.
-
Inhibition of invasion-associated thromboxane synthase sensitizes experimental gliomas to gamma-radiation.J Neurooncol. 2009 Feb;91(3):241-9. doi: 10.1007/s11060-008-9708-0. Epub 2008 Sep 30. J Neurooncol. 2009. PMID: 18825315
-
Celecoxib enhances radiosensitivity in medulloblastoma-derived CD133-positive cells.Childs Nerv Syst. 2010 Nov;26(11):1605-12. doi: 10.1007/s00381-010-1190-2. Epub 2010 Jun 5. Childs Nerv Syst. 2010. PMID: 20526717
-
Radiosensitization in prostate cancer: mechanisms and targets.BMC Urol. 2013 Jan 26;13:4. doi: 10.1186/1471-2490-13-4. BMC Urol. 2013. PMID: 23351141 Free PMC article. Review.
-
Cyclo-oxygenase-2 and its inhibition in cancer: is there a role?Drugs. 2007;67(6):821-45. doi: 10.2165/00003495-200767060-00001. Drugs. 2007. PMID: 17428102 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials